Literature DB >> 16675092

The length of menstrual bleeding and the risk of urogenital infections in the context of the activity of hemoglobin-derived microbicidal peptides.

Lukasz Wicherek1, Paweł Mak2, Marek Klimek1, Tomasz Banaś1.   

Abstract

OBJECTIVE: Well-known natural unspecific antimicrobial factors acting in the vagina are additionally reinforced during menstrual bleeding by hemocidins--a recently discovered novel class of microbicidal peptides generated proteolytically from hemoglobin. The aim of the presented research was to investigate the relation between the average length of menstrual bleeding and the frequency of urogenital infections. We expected that the shorter menstrual bleeding might increase the risk of urogenital infections because is synonymous with the shorter period of exposition on bactericidal action of hemocidins. STUDY
DESIGN: The study contains statistical analysis of an average declared length of menstrual bleeding in the group of 267 young, sexually active women with the symptoms of urogenital infections. The control group consisted of 300 young healthy women.
RESULTS: The length of menstrual bleeding in the group of patients with urogenital infections (average 4.35 days) was statistically significantly shorter than in the control group (average 4.95 days). The average length of the menstrual cycle was equal and counted ca. 28 days in both groups.
CONCLUSION: The length of menstrual bleeding seems to be a significant factor in the vaginal ecology maintenance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675092     DOI: 10.1016/j.ejogrb.2006.03.012

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Expression of hemoglobin-α and β subunits in human vaginal epithelial cells and their functional significance.

Authors:  Debarchana Saha; Swanand Koli; Mandar Patgaonkar; Kudumula Venkata Rami Reddy
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

2.  HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.

Authors:  Tahir Bashir; Mandar Patgaonkar; Selvaa C Kumar; Achhelal Pasi; Kudumula Venkata Rami Reddy
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.